Support AVeta Medical's Innovative Solutions for GSM on Spark Crowdfunding
AVeta Medical is a Galway-based medical device start-up focused on developing innovative, pharma-free treatments for Genitourinary Syndrome of Menopause (GSM), a condition that affects many of the 1.1 billion postmenopausal women and breast cancer survivors globally. The company was founded by Paula Newell, who identified a significant need for safer, more effective, and affordable treatments for this condition during her participation in the BioInnovate program at the University of Galway, which is affiliated with the prestigious Stanford BioDesign program.
AVeta Medical's flagship product is a non-pharma, non-hormonal, self-administered treatment designed to alleviate the symptoms of GSM, such as dryness, pain during intercourse, inflammation and irritation. Following regulatory approval, the device is intended for home use and requires only a 5-minute treatment over four consecutive months to obtain up to a 10-month relief, making it convenient, easy to use and discreet.
The company has successfully completed pre-clinical trials and a First in Human clinical trial with excellent results and is working towards FDA approval, with plans to launch the product in Europe and the US. AVeta Medical has also secured significant funding, including a €2.5 million grant from the European Innovation Council Accelerator, to support its development and market launch efforts. AVeta is now opening a unique fundraising round to offer members of the public the opportunity to join AVeta Medical in bringing this innovative and disruptive solution to market. The funds will be used to complete the Randomized control clinical trials ahead of FDA and MDR submissions for market release.
AVeta Medical is currently crowdfunding and you can support their campaign on Spark Crowdfunding.
Key highlights:
80% of women globally over 51 years of age are affected by GSM discomfort.
The US attainable market alone is worth over $2 billion
AVeta Medical’s product uniquely delivers a hormone-free, safe, affordable and targeted therapy.
The company has filed for patent protection.
European EIC €2.5M grant funding secured in 2021
Early in-human trials demonstrate patient relief for 80% of trialists.
The AVeta team has an impressive mix of experience in medical device development, completing clinical trials and working with regulatory bodies like the FDA, TUV, and NSAI.
AVeta Medical Establishes Board of Directors with Experienced Leaders
AVeta Medical is pleased to announce the establishment of its Board of Directors, comprising highly experienced professionals in the medical and healthcare industries. This strategic move is aimed at preparing for the commercialization of AVeta's innovative medical solutions.
Dr. Karen Noblett, M.D., has been appointed as the new Chairperson of the Board. Dr. Noblett is Board Certified in OB/GYN and Female Pelvic Medicine and Reconstructive Surgery. She has a distinguished career in academic medicine. Dr. Noblett serves as Chief Medical Officer of Axonics, which was acquired by Boston Scientific for $3.4 bn in January 2024. She was the founding Chair and Professor of the Department of OB/GYN in the School of Medicine at the University of California, Riverside, from 2014-2017. She was also a professor in the OB/GYN Department and Fellowship and Division Director for Urogynecology at the University of California, Irvine, as well as the Interim Chief Medical Officer. Dr. Noblett completed her Master of Advanced Studies in Clinical Research at the University of California, San Diego, and has published over 50 peer-reviewed journal articles and authored multiple book chapters.
Joining the board alongside Dr. Noblett are Jane Kiernan and Eileen Duffy. Jane Kiernan brings over 30 years of executive and management leadership in healthcare, having held significant roles in both public and private companies. Jane holds a position alongside Dr. Noblett on the Board of Directors of Axonics. She is the co-founder of K2 Biotechnology Ventures and has previously served as the CEO of Salter Labs and on the Board of Directors of Nasdaq-listed American Medical Systems (AMS). She served as Global General Manager at Baxter International. Kiernan has a proven track record of driving growth and innovation in the healthcare sector and holds a B.S. degree in business from Southern Methodist University.
Eileen Duffy brings to the board over 25 years of global commercial experience in the Lifesciences and Medtech Industries, through executive leadership roles at Baxter International, and Aerogen, Ireland's largest indigenous medical device company, She brings deep commercial experience and a proven track record of building and growing companies across therapeutic areas and geographies. Eileen currently serves on the Board of Directors of Sarnova, a Patricia Industries company. Eileen has also held various global senior executive leadership positions at Baxter International, where she worked with Jane Kiernan. She received her Master’s in Business Administration (MBA) from University College Dublin (Ireland) and holds a Diploma in Corporate Governance from The Corporate Governance Institute.
These new board members join AVeta Medical's Founder, Paula Newell, and Co-Founder and CEO, Brian Ledwith, to expand the board and guide the company through its next phase of growth and commercialization.
Find out more about AVeta Medical on their website.
Support AVeta Medical on Spark Crowdfunding.
For more information, please contact: info@avetamedical.com